Genetic effects of hydralazine.
Hydralazine and its acetone condensation product (ACP) were found to induce base-pair substitution mutations in the Salmonella/microsomal activation test system and to display genetic toxicity in the PolA+/A- test system. Incubation with a rat-liver microsomal fraction did not affect the genetic toxicity of either compound. Other derivatives of hydralazine, including the major metabolite, 3-hydroxy-methyl-s-triazolo-[3,4a]phthalazine, did not yield any evidence of genetic toxicity nor were they metabolically convertible to a toxic product. Therefore, individuals who convert hydralazine to MTP slowly, the "slow acetylators", would be expected to be at risk.
D004353:Drug Evaluation, Preclinical; D005821:Genetic Techniques; D006830:Hydralazine / Q000494:pharmacology*; D009153:Mutagens; D012486:Salmonella typhimurium / Q000235:genetics
D009153:Mutagens; D006830:Hydralazine